Onkológia 4/2017

Cardiovascular complications caused by treatment of hematologic malignancies

Novel therapeutic approaches have led to an improvement in survival of hematologic malignancies; however, this success can often require a cost – unexpected acute, chronic and late adverse cardiovascular events. Modern treatment of hematooncologic patients may be associated with left ventricular dysfunction, heart failure, coronary artery disease including acute coronary syndrome, arterial hypertension, thromboembolic complications, peripheral artery disease, pulmonary hypertension, valvular defects as well as arrhythmias. This minireview will summarize cardiovascular issues that may arise mainly after novel strategies used in the field of hematooncology.

Keywords: targeted therapy, immunomodulatory drugs, proteasome inhibitors, immunotherapy, cardiovascular complications